Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61–71.
   PubMed Web of Science ®Google Scholar
• Daskivich TJ, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2011;117:2058–66.
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301–8.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;84:125–9.
   PubMed Web of Science ®Google Scholar
• Haugnes HS, Melby B, Larsen KM, Langdal I, Rasi M, Bremnes RM. Assessment of late urinary, bowel and sexual function after dose escalation from 70 to 76 Gy using image-guided radiotherapy in curative treatment of prostate cancer. Scand J Urol Nephrol 2012;46:124–32.
   PubMed Web of Science ®Google Scholar
• Budaus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol 2012;61:112–27.
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.
   PubMed Web of Science ®Google Scholar
• Aznar MC, Petersen PM, Logadottir A, Lindberg H, Korreman SS, Kjaer-Kristoffersen F, et al. Rotational radiotherapy for prostate cancer in clinical practice. Radiother Oncol 2010;97:480–4.
   PubMed Web of Science ®Google Scholar
• Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843–8.
   PubMed Web of Science ®Google Scholar
• Fransson P, Tavelin B, Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy-induced side effects. Support Care Cancer 2001;9:187–98.
   PubMed Web of Science ®Google Scholar
• Hamoen EH, De Rooij M, Witjes JA, Barentsz JO, Rovers MM. Measuring health-related quality of life in men with prostate cancer: a systematic review of the most used questionnaires and their validity. Urol Oncol 2014; Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Fransson P, Lund JA, Damber JE, Klepp O, Wiklund F, Fossa S, et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol 2009;10:370–80.
   PubMed Web of Science ®Google Scholar
• Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61.
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Jackson A, Spratt DE, Oh JH, Munck Af Rosenschold P, Kollmeier M, et al. Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity. Eur Urol 2013;64:931–8.
   PubMed Web of Science ®Google Scholar
• Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019–34.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006;176:1415–19.
   PubMed Web of Science ®Google Scholar
• Fransson P, Bergstrom P, Lofroth PO, Widmark A. Five-year prospective patient evaluation of bladder and bowel symptoms after dose-escalated radiotherapy for prostate cancer with the BeamCath technique. Int J Radiat Oncol Biol Phys 2006;66:430–8.
   PubMed Web of Science ®Google Scholar
• Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2013;85:686–92.
   PubMed Web of Science ®Google Scholar
• Sveistrup J, Af Rosenschold PM, Deasy JO, Oh JH, Pommer T, Petersen PM, et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol 2014;9:44.
   PubMed Web of Science ®Google Scholar
• Fransson P, Widmark A. Does one have a sexual life 15 years after external beam radiotherapy for prostate cancer? Prospective patient-reported outcome of sexual function comparison with age-matched controls. Urol Oncol 2011;29:137–44.
   PubMed Web of Science ®Google Scholar
• Fransson P, Widmark A. Late side effects unchanged 4–8 years after radiotherapy for prostate carcinoma: a comparison with age-matched controls. Cancer 1999;85:678–88.
   PubMed Web of Science ®Google Scholar
• Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 2007;178:597–601.
   PubMed Web of Science ®Google Scholar
• Lester-Coll NH, Goldhaber SZ, Sher DJ, D'Amico AV. Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis. Cancer 2013;119:1808–15.
   PubMed Web of Science ®Google Scholar